Investigational drug · Phase 3
coformulation favezelimab
Also called: MK-4280A
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Small Cell Lung Carcinoma, Solid Tumors, Hematologic Malignancies.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
9
Any phase or sponsor naming "coformulation favezelimab"
First trial start
2018
Aug 21, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "coformulation favezelimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Small Cell Lung Carcinoma
- Solid Tumors
- Hematologic Malignancies
- Esophageal Squamous Cell Carcinoma (ESCC)
Approved drugs for the same conditions: Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "coformulation favezelimab" as an intervention, largest first.
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02720068 · 481 participants · Start May 2, 2016 · Primary completion Mar 15, 2024
Drug: Favezelimab; Pembrolizumab and 6 more · For: Neoplasms
- Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04626479 · 393 participants · Start Dec 16, 2020 · Primary completion Aug 10, 2026
Drug: Pembrolizumab; Favezelimab/Pembrolizumab and 4 more · For: Carcinoma, Renal Cell
Sites: San Francisco, California; New Haven, Connecticut; Chicago, Illinois · 55 sites in all
- Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04305054 · 335 participants · Start Jul 1, 2020 · Primary completion May 18, 2026
Drug: Pembrolizumab; Vibostolimab and 4 more · For: Melanoma
Sites: Los Angeles, California; Santa Monica, California; Aurora, Colorado · 60 sites in all
- Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)Pivotal-lookingTerminated
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02625961 · 296 participants · Start Feb 10, 2016 · Primary completion Nov 5, 2025
Drug: Pembrolizumab; Pembrolizumab/vibostolimab coformulation and 1 more · For: Bladder Cancer
- Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04626518 · 263 participants · Start Dec 17, 2020 · Primary completion Jul 23, 2026
Drug: Pembrolizumab; MK-4830 and 4 more · For: Carcinoma, Renal Cell
Sites: San Francisco, California; New Haven, Connecticut; Chicago, Illinois · 51 sites in all
- Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06036836 · 163 participants · Start Sep 29, 2023 · Primary completion Mar 12, 2026
Drug: favezelimab/pembrolizumab; pembrolizumab and 1 more · For: Solid Tumor; Cutaneous Squamous Cell Carcinoma; Endometrial Cancer
Sites: New Haven, Connecticut; Boston, Massachusetts; New Brunswick, New Jersey · 44 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04303169 · 146 participants · Start Jun 26, 2020 · Primary completion Sep 24, 2025
Drug: Pembrolizumab; Vibostolimab and 4 more · For: Melanoma
Sites: Los Angeles, California; Santa Monica, California; Aurora, Colorado · 29 sites in all
- Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04938817 · 110 participants (planned) · Start Aug 19, 2021 · Primary completion Dec 10, 2029
Drug: coformulation pembrolizumab/quavonlimab; lenvatinib and 3 more · For: Small Cell Lung Carcinoma
Sites: Gilbert, Arizona; Atlanta, Georgia; Fort Wayne, Indiana · 48 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05342636 · 90 participants · Start Jul 27, 2022 · Primary completion Dec 5, 2025
Drug: Pembrolizumab; Coformulation favezelimab/pembrolizumab and 4 more · For: Esophageal Squamous Cell Carcinoma (ESCC)
Sites: Natal, Brazil; Porto Alegre, Brazil; São Paulo, Brazil · 46 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Small Cell Lung Carcinoma
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- ObrixtamigBI 764532Phase 36 trials
Boehringer Ingelheim · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
- AL8326Phase 34 trials
Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- MK-4830Phase 210 trials
Merck & Co. · Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Esophageal Squamous Cell Carcinoma
- CBX-12Phase 21 trial
Cybrexa Therapeutics · Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma
- coformulation pembrolizumabPhase 21 trial
Merck & Co. · Small Cell Lung Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.